SCHEMBL24368305

SCHEMBL24368305

N#Cc1cc(CC(=O)N2CCC(n3c(=O)[nH]c4cccc(C(F)(F)F)c43)CC2)cc2cccnc12

nearest known ligand 0.42

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CALCRL Q16602 14/20 0.42
▸ LMNA P02545 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ HSD11B1 P28845 2/20 0.41
▸ CHRM1 P11229 2/20 0.39
▸ TNKS O95271 1/20 0.38
▸ PARP1 P09874 1/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29518774 1.00 CALCRL (0.42) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL24368261 0.91 LMNA (0.44) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL29619910 0.91 LMNA (0.44) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL29518522 0.89 LMNA (0.42) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL29518107 0.89 CALCRL (0.43) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL24368234 0.89 CALCRL (0.43) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL24368245 0.89 LMNA (0.42) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL22605644 0.85 PLD2 (0.45) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL29518321 0.85 PLD2 (0.45) CALCRLLMNAMAPK1HTTHSD11B1
SCHEMBL24368272 0.82 LMNA (0.41) CALCRLLMNAMAPK1HTTHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240391940-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME GENEROS BIOPHARMA LTD. (GB) 2024-11-28 — — US disclosed
EP-4234544-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME Generos Biopharma Ltd. (KY) 2023-08-30 — — EP disclosed
EP-4234544-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME Generos Biopharma Ltd. (KY) 2023-08-30 — — EP disclosed
CN-116457347-A Compound containing condensed rings, application thereof and composition containing compound 健艾仕生物医药有限公司 2023-07-18 — — CN disclosed
CN-114478482-A Compound containing condensed ring, application thereof and composition containing compound 健艾仕生物医药有限公司 2022-05-13 — — CN disclosed
WO-2022083731-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2022-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240391940-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME STAT5A, STAT5B, JAK2 CALCRL 3487/4885LMNA 4799/4885MAPK1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback